Ironwood Pharma (IRWD) Misses Q2 EPS by 6c, Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
August 3, 2017 4:01 PM EDTLINZESS® (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-year and $168 million in U.S. net sales
Positive IW-3718 Phase IIb top-line data in uncontrolled GERD support advancement into Phase III
Multiple additional catalysts expected in 2H 2017, including DUZALLO® (lesinurad and allopurinol) approval and launch, three mid-stage data readouts and four mid- to late-stage trial initiations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
